---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-23-000089"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:55:11.348968+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q2 revenue $35.2M (-8.5% YoY); raises software revenue guidance, cuts drug discovery outlook

## Summary
- Net income $4.3M vs net loss $47.7M YoY, driven by $45.0M other income and $20.4M tax benefit.
- Non-GAAP net loss $56.8M vs $43.8M YoY; operating expenses rose 23.7% to $74.9M.
- Software revenue growth guidance raised to 15%-18%; drug discovery revenue guidance cut to $50M-$70M from $70M-$90M.
- IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial for AML/MDS expected in 2023.
- Zai Lab elected not to continue discovery collaboration; program returned to wholly-owned by Schrödinger.

## SEC filing metadata
- accession: 0001490978-23-000089
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/0001490978-23-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/sdgr-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-23-000089
- JSON: https://secwatch.observer/filing/0001490978-23-000089.json
- Plain text: https://secwatch.observer/filing/0001490978-23-000089.txt

## Key facts
- Earnings Releases
  Schrodinger, Inc. reported the quarter ended on June 30, 2023 results: revenue $35.2 million, net income $4.3 million. Guidance raised.
  - Period: the quarter ended on June 30, 2023
  - Revenue: $35.2 million
  - Net income: $4.3 million
  - Guidance: raised
  - Result: reported results
  source text: Quarter 2023 Financial Results Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance New York, August 2, 2023 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/0001490978-23-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.